Y-mAbs Therapeutics Inc. (YMAB): Good time to sell it?

0
42

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) changes shares on Friday trading session, with a change of 3.06% or $1.43 shares. The trading starts at $47.14 and closed at $46.70 throughout the day. The trading session low price was $46.01 and day high was $48.29 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.39 million while its average volume is 242.97K. In other hand, the YMAB market cap reached to $1.86B. While, its current target price is $48.13 according to WSJ.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 14.24% and up 26.03% for month. Its quarterly performance was 148.48% above, while its half year performance is up 56.37%. YMAB yearly performance stood at positive 124.17% and rise 54.02% for year-to-date. Current recommendation for Y-mAbs Therapeutics Inc. is 1.60.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. YMAB EPS (TTM) for 12-month is -2.49. EPS for this year is -53.10%, while for the next year its value is -1.07. Its EPS Q/Q reached -41.30%.

Let’s take a look on the analyst recommendations on YMAB for the current month and previous month. For the current month, 9 of 10 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 9 analysts participate in stock recommendation. Out of 9, 0 rated it sell, 8 rated it as Buy and 1 as Hold Ratings. On the other hand, target price ranges from $39.00-$52.00. Average target price for YMAB was reached at $45.56.

Wellington Management Company, LLP, Sofinnova Investments, Inc. and Blackrock Inc. are the top three holders in Y-mAbs Therapeutics Inc. (YMAB) stock. On Mar 30, 2020, Wellington Management Company, LLP has 2.74 million shares which valued 71.63 million. On Mar 30, 2020, Sofinnova Investments, Inc. owned 2.19 million shares which valued at 57.27 million. On Mar 30, 2020, Blackrock Inc. has a total of 1.98 million shares which valued at 51.68 million. In the end, Blackrock Inc. have 4.98% shares outstanding of Y-mAbs Therapeutics Inc. (YMAB) on Mar 30, 2020. The insider ownership moved to 15.00% and institutional holding shifted to 53.90%.

The company posted an EPS (TTM) of -2.49. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of -0.68, while -0.53 EPS posted a year ago period. Analyst Estimated EPS for YMAB published in the report was -0.79–0.54 during the same period. Comparing with last year, the average estimated EPS was -0.53 which is higher than -0.66 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for YMAB rise 54.08% for period of 200 days. SMA for 50 days was 28.19% which is showing green signal, while SMA-20 was 14.31%. The moving average value for Y-mAbs Therapeutics Inc. (YMAB) is 32.58 and 40.18 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in YMAB stock. On Jun 15, Gad Thomas, President and Chairman, sold 4,000 trading shares at the cost of $43.45, which valued at 0.17 million. On Jun 04, Gad Thomas, President and Chairman, sold 4,000 shares at the cost of $41.61, with total shares of 720,000. On May 27, Gad Thomas, President and Chairman, sold 50,000 shares at the cost of 39.01. After this transaction, Gad Thomas total shares reached to 724,000 which valued at 1.95 million.